Friday, October 14, 2016 8:45:30 PM
pts previously treated with checkpoint inhibitors were excluded.
Among 19 pts who were treatment-naive for advanced melanoma (M1c 53%), 4 CRs, 7 PRs, and 3 SDs were observed. Responses were observed in all epac dose cohorts ≥50 mg BID and all sites of target lesions including liver, lung, and lymph nodes. All responses are confirmed and ongoing (median follow-up [min, max]: 42 wks [31.7, 75.9]). Median PFS has not been reached. Responses were also observed in pts previously treated for advanced melanoma (n = 3; 1 CR, 1 SD) and pts with NSCLC (n = 12; 5 PRs, 2 SDs), RCC (n = 11; 3 PRs, 5 SDs), endometrial adenocarcinoma (n = 7; 1 CR, 1 PR), TCC (n = 5; 3 PRs), TNBC (n = 3; 2 SDs), SCCHN (n = 2; 1 PR, 1 SD).
https://cslide.ctimeetingtech.com/library/esmo/browse/search/CCe#2z9580Ho
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM